Key Points
- Insider sale: Krishnan Viswanadhan sold 2,959 Agios (NASDAQ:AGIO) shares on March 5 at an average price of $27.80 for $82,260.20, cutting his ownership by 36.53% to 5,141 shares valued at about $142,920.
- Analyst outlook: Analysts are mixed (6 Buy, 4 Hold, 1 Sell) with a MarketBeat consensus of "Hold" and a consensus price target of $40.67, while recent targets range from Goldman Sachs' $25 to HC Wainwright's $65.
- Institutional activity: Large investors have been increasing positions — notably Wellington Management raised its stake 485.5% to 2.47 million shares (~$99.2M) and State Street holds about 3.11 million shares (~$84.6M).
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) insider Krishnan Viswanadhan sold 2,959 shares of the firm's stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $27.80, for a total value of $82,260.20. Following the sale, the insider directly owned 5,141 shares of the company's stock, valued at $142,919.80. This trade represents a 36.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Agios Pharmaceuticals Stock Performance
Shares of NASDAQ AGIO opened at $28.53 on Tuesday. The stock has a market cap of $1.67 billion, a price-to-earnings ratio of -4.01 and a beta of 0.89. The business has a 50 day simple moving average of $28.08 and a 200 day simple moving average of $33.15. Agios Pharmaceuticals, Inc. has a 52 week low of $22.24 and a 52 week high of $46.00.
Analyst Ratings Changes
Several research firms have commented on AGIO. Wall Street Zen raised shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, February 14th. HC Wainwright raised their price target on shares of Agios Pharmaceuticals from $62.00 to $65.00 and gave the company a "buy" rating in a report on Thursday, February 12th. Bank of America lifted their price objective on shares of Agios Pharmaceuticals from $32.00 to $34.00 and gave the company a "buy" rating in a research note on Wednesday, December 24th. The Goldman Sachs Group decreased their price objective on shares of Agios Pharmaceuticals from $40.00 to $25.00 and set a "neutral" rating for the company in a report on Thursday, November 20th. Finally, Citigroup increased their target price on shares of Agios Pharmaceuticals from $38.00 to $46.00 and gave the stock a "buy" rating in a research report on Thursday, March 5th. Six analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $40.67.
View Our Latest Analysis on Agios Pharmaceuticals
Institutional Investors Weigh In On Agios Pharmaceuticals
Large investors have recently added to or reduced their stakes in the stock. Wellington Management Group LLP lifted its stake in shares of Agios Pharmaceuticals by 485.5% in the third quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company's stock worth $99,203,000 after buying an additional 2,049,287 shares during the last quarter. MPM Bioimpact LLC acquired a new position in Agios Pharmaceuticals in the 4th quarter valued at $35,478,000. State Street Corp raised its holdings in Agios Pharmaceuticals by 37.4% in the 4th quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company's stock worth $84,604,000 after acquiring an additional 845,433 shares during the period. TCG Crossover Management LLC raised its holdings in Agios Pharmaceuticals by 105.2% in the 3rd quarter. TCG Crossover Management LLC now owns 1,430,041 shares of the biopharmaceutical company's stock worth $57,402,000 after acquiring an additional 733,038 shares during the period. Finally, Capital International Investors acquired a new position in Agios Pharmaceuticals during the 4th quarter worth $19,159,000.
About Agios Pharmaceuticals
(
Get Free Report)
Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company's scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.
Agios's lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
